Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvisomant vs Sandostatin LAR in Naive Acromegaly
NCT00068042Phase 4Completed
- Sponsor
- Pfizer
- Start
- Apr 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 4, randomised, open-label trial of pegvisomant in acromegaly (2 arms), sponsored by Pfizer. Primary endpoint: Percentage of patients with normal IGF-1 concentration at 52 weeks. Started Apr 2003; status: completed.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00068042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068042.